Additional data demonstrates positive results of pridopidine drug on Total Functional Capacity
Additional data demonstrates positive results of pridopidine drug on Total Functional Capacity Positive results from additional analyses of PRIDE-HD and Open-HART trials with pridopidine published in a peer-reviewed journal, The Journal of Huntington's Disease. Exploratory additional efficacy data show pridopidine (45 mg bid) to be the first drug to exert a significant and clinically meaningful beneficial effect on Total Functional Capacity (TFC). Results from the Open-HART trial demonstrate the potential durability of the effect of pridopidine with less TFC decline over 5 years compared to t...